兰州大学机构库 >第二临床医学院
柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查
Alternative TitleSulphasalazine in patients with rheumatoid arthritis in China: a cross-sectional study
2012-04-18
Source Publication北京大学学报(医学版)   Impact Factor & Quartile Of Published Year  The Latest Impact Factor & Quartile
ISSN1671-167X
Volume44Issue:2Pages:188-194
Abstract目的:调查和分析类风湿关节炎(rheumatoid arthritis,RA)患者治疗中柳氮磺吡啶(sulphasalazine,SSZ)的使用及其不良反应发生情况。方法:采用流行病学现况调查的研究方法,对北京大学人民医院等全国21家三级甲等医院2009年7月至2010年12月于风湿免疫科门诊及病房就诊的1 096例RA患者进行问卷调查,并详细记录患者的一般资料和临床特点,分析其中160例使用SSZ患者的临床特点、副作用发生情况、SSZ使用现况及联合用药种类和时间等数据。结果:160例患者使用SSZ治疗,使用比例为14.6%。该组患者男女之比为1∶7,平均发病年龄为(46.1±15.0)岁,平...
Other AbstractOBJECTIVE: To investigate the medication status of rheumatoid arthritis (RA) patients and to analyze the clinical use of sulphasalazine (SSZ) and the adverse effect.METHODS: A total of 1 096 outpatients and inpatients diagnosed with RA were investigated in 21 hospitals all over China from July 2009 to December 2010, including gender, age of onset, clinical manifestations, as well as the clinical characteristics and medication status of 160 RA patients who received SSZ therapy.RESULTS: In the group of 160 patients who received SSZ, the male-to-female ratio was 1:7, The average age at onset was (46.1±15.0) years, while the average course was (9.9±7.8) years. The average dose of sulphasalazine was (1.87±0.52) g/d for a mean duration of (26.3± 14.6) months. Only 17% (27/160) of the patients received SSZ monotherapy. Methotrexate (63.1%), leflunomide (36.2%) and hydroxychloroquine (18.1%) were most commonly used combination drugs. And 36.2% (58/160) of the patients used the two-drug combination of methotrexate plus sulphasalazine .In this group, 41.9% (67/160) once used SSZ but withdrew for adverse events and other reasons, while 17.5% (28/160) withdrew for adverse events, of which the most common were gastrointestinal (8.8%), skin (3.8%) and liver toxicity (3.1%).CONCLUSION: Sulphaszlazine is not a common choice in the RA therapeutics in China, and the average dose of SSZ is lower than the standard dose of 2 to 3 g/d . The adverse events of SSZ are common; however, there are few severe adverse events or threat to life,SSZ is relatively safe in clinical practice.
Keyword柳氮磺吡啶 关节炎,类风湿 横断面研究
Subject AreaGeriatrics & Gerontology ; Pharmacology & Pharmacy ; Rheumatology
Publication PlaceBEIJING
Indexed ByPubMed ; MEDLINE ; CSCD
Language中文
First Inst
Funding Project国家科技支撑计划
Host of Journal北京大学
Project Number国家“十一五”科技支撑计划项目(2008BAI59B01)资助~~
CSCD IDCSCD:4503646
Funding OrganizationMOST
PMID 22516985
IRIDCNKI:0050465
Department
北京大学人民医院风湿免疫科;
北京大学首钢医院多顶街社区卫生中心全科;
山西医科大学第二医院风湿免疫科;
包头医学院第一附属医院风湿免疫科;
中日友好医院风湿免疫科;
第四军医大学西京医院风湿免疫科;
河北医科大学第二医院风湿免疫科;
北京大学第三医院风湿免疫科;
河北医科大学第三医院风湿免疫科;
华北煤炭医学院附属开滦医院风湿免疫科...更多
Citation statistics
Cited Times:2[CSCD]   [CSCD Record]
Document Type期刊论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/174713
Collection第二临床医学院
Recommended Citation
GB/T 7714
刘田,王秀茹,安媛,等. 柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查[J]. 北京大学学报(医学版),2012,44(2):188-194.
APA 刘田.,王秀茹.,安媛.,周云杉.,张晓盈.,...&栗占国.(2012).柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查.北京大学学报(医学版),44(2),188-194.
MLA 刘田,et al."柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查".北京大学学报(医学版) 44.2(2012):188-194.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[刘田]'s Articles
[王秀茹]'s Articles
[安媛]'s Articles
Baidu academic
Similar articles in Baidu academic
[刘田]'s Articles
[王秀茹]'s Articles
[安媛]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[刘田]'s Articles
[王秀茹]'s Articles
[安媛]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.